Brief: China Nt Pharma Says Finalized Major Terms Of Potential Acquisition
14/06/2022 16:15
June 14 (Reuters) - China NT Pharma:
* CO FINALIZED MAJOR TERMS OF POTENTIAL ACQUISITION OF
COMMERCIALISATION RIGHT OF CERTAIN MONOCLONAL ANTIBODY PRODUCTS
* CLINICAL-STAGE BIOPHARMACEUTICAL CO INCORPORATED IN USA TO
GRANT
EXCLUSIVE & PERPETUAL LICENSE TO UNIT
* LICENSE TO COMMERCIALISE CERTAIN MONOCLONAL ANTIBODY
PRODUCTS IN
PRC, HONG KONG, MACAU, TAIWAN, SINGAPORE, MALAYSIA AND THAILAND
Source text for Eikon: ID:nHKS5y7mtV
Further company coverage: 1011.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China NT Pharma
See all newsBrief: China NT Pharma Receives Cietac Beijing Arbitration Award On July 20
Brief: China NT Pharma Establishes Formal Whistleblowing Policy
Brief: China NT Pharma Group Says Zhang Bozhi Resigns As CEO
Brief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY